These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 1030082)

  • 1. [Plasma level of pindolol (Visken) under long-term treatment, computed from pharmacokinetics after a single dose].
    Gugler R; Bodem G; Dengler HJ
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1689-91. PubMed ID: 1030082
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacokinetics of unchanged pindolol in patients with impaired renal function.
    Ohnhaus EE
    Br J Pharmacol; 1973 Mar; 47(3):620P-621P. PubMed ID: 4730841
    [No Abstract]   [Full Text] [Related]  

  • 3. Single and multiple dose pharmacokinetics of pindolol.
    Gugler R; Bodem G
    Eur J Clin Pharmacol; 1978 Mar; 13(1):13-6. PubMed ID: 639828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of pindolol in a group of elderly hypertensive patients (author's transl)].
    Salathé B; Kerle FH
    Aktuelle Gerontol; 1980 Oct; 10(10):443-7. PubMed ID: 6110350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pindolol eye drops (Glauco-Visken) - half year's results in glaucoma therapy].
    Merté HJ; Stryz JR; Mertz M
    Klin Monbl Augenheilkd; 1984 Mar; 184(3):227-32. PubMed ID: 6374263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure.
    Lima JJ; Binkley PF; Johnson J; Leier CV
    J Clin Pharmacol; 1986 Apr; 26(4):253-7. PubMed ID: 3700683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stereoselective determination of racemic pindolol in rat plasma and its application].
    Hasegawa R; Kushiya M; Komuro T; Isaka H
    Eisei Shikenjo Hokoku; 1987; (105):71-3. PubMed ID: 3449175
    [No Abstract]   [Full Text] [Related]  

  • 8. The long-term effect of isradipine in pindolol-treated patients.
    Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Hansson L
    J Hypertens Suppl; 1987 Dec; 5(5):S567-70. PubMed ID: 2965231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pindolol in hypertension: twice-daily versus thrice-daily dosage.
    Waal-Manning HJ; Wood AJ
    Med J Aust; 1975 Aug; 2(7):274-5. PubMed ID: 1160793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pindolol (Visken) on blood pressure and plasma renin activity in various forms of hypertension].
    Werning C; Vetter H
    Adv Clin Pharmacol; 1976; 11():54-60. PubMed ID: 1032571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ergometric evaluation of the cardioprotective effect of pindolol in coronary disease. Comparison of 2 galenic forms].
    Mérier GR; Perrenoud JJ
    Schweiz Med Wochenschr; 1988 Jul; 118(26):1016-20. PubMed ID: 3413461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of mepindolol in healthy volunteers after oral doses of mepindolol sulphate.
    Krause W; Schwartzkopff W
    Arzneimittelforschung; 1983; 33(9):1306-7. PubMed ID: 6685513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The antihypertensive action of the beta adrenergic blocking agent Visken (pindolol, LB 46) in mild and moderate hypertension].
    Török E; Jávor T; Szám I; Gábor G
    Orv Hetil; 1976 Mar; 117(10):593-8. PubMed ID: 1250586
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of pindolol absorption in malabsorption syndromes].
    Evard D; Le Quintrec Y; Aubry JP; Cheymol G; Cheymol A
    Gastroenterol Clin Biol; 1983 Apr; 7(4):398-404. PubMed ID: 6873552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report on Australian multicentre trial: once daily dose of Visken.
    Thorpe P
    Aust Fam Physician; 1981 Apr; 10(4):243, 245. PubMed ID: 7247858
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hemodynamic long-term effects of a beta-receptor blockader (Pindolol) in primary essential hypertension].
    Klein WW; Brandt D; Fluch N; Goebel R; Holzer H; Pöch G
    Adv Clin Pharmacol; 1976; 11():79-85. PubMed ID: 1032573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)].
    Persson I; Ulrich J
    Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
    Bonelli J; Hitzenberger G; Krause W; Wendt H; Speck U
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of tobanum and visken in ischemic heart disease with extrasystole].
    Korkushko OV; Shatilo VB; Butenko AG
    Sov Med; 1989; (12):66-8. PubMed ID: 2483591
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.
    Greendyke RM; Gulya A
    J Clin Psychiatry; 1988 Mar; 49(3):105-7. PubMed ID: 3346197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.